SCHEMBL353387

SCHEMBL353387

COCCn1nc(C)c(C(=O)O)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.53
LMNA P02545 3/20 0.42
ALDH1A1 P00352 2/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HBB P68871 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 2/20 0.40
HCAR3 P49019 1/20 0.40
NPC1 O15118 1/20 0.40
P2RX7 Q99572 1/20 0.39
GAA P10253 2/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
ALKBH1 Q13686 1/20 0.36
NR3C1 P04150 1/20 0.36
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354838 0.90 POLB (0.50) POLBLMNAALDH1A1ALOX15TSHR
SCHEMBL353583 0.89 POLB (0.49) POLBLMNAALDH1A1ALOX15TSHR
SCHEMBL20550955 0.84 MAPK1 (0.43) POLBLMNAALDH1A1ALOX15TSHR
SCHEMBL20378348 0.81 POLB (0.57) POLBLMNAALDH1A1MEN1KMT2A
SCHEMBL19119188 0.81 POLB (0.57) POLBLMNAALDH1A1MEN1KMT2A
SCHEMBL28015987 0.78 POLB (0.54) POLBLMNAALDH1A1HSD17B10MEN1
SCHEMBL8306766 0.77 POLB (0.60) POLBLMNAALDH1A1MEN1KMT2A
SCHEMBL4754838 0.75 POLB (0.51) POLBLMNAALDH1A1MAPK1MEN1
SCHEMBL20550959 0.75 MAPK1 (0.41) POLBLMNAALDH1A1TSHRMAPK1
SCHEMBL15080866 0.74 ALDH1A1 (0.46) ALDH1A1MEN1KMT2ANPC1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 EP disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-8148380-B2 Antibacterial amide and sulfonamide substituted heterocyclic urea compounds CRESTONE, INC. (US) 2012-04-03 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds CRESTONE, INC. (US) 2012-01-19 US disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015941-A1 Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds NAAA, AADAC, RPSA POLB 1884/4885LMNA 4293/4885ALDH1A1 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.